

DYNAVAX TECHNOLOGIES CORP

Form 8-K

February 18, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 18, 2014

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware	33-0728374
(State or other jurisdiction of incorporation)	(IRS Employer Identification No.)

2929 Seventh Street, Suite 100

Berkeley, CA 94710-2753

(Address of principal executive offices, including zip code)

(510) 848-5100

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01. Other Events

On February 18, 2014, we issued a press release titled "Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV™." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

The following exhibit is furnished herewith:

EX-99.1 Press Release, dated February 18, 2014, titled "Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV™".



Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation  
Date February 18, 2014 By: /s/ Michael S. Ostrach  
Michael S. Ostrach  
Vice President

---

EXHIBIT INDEX

Exhibit No. Description

EX-99.1 Press Release, dated February 18, 2014, titled "Dynavax Announces Withdrawal of European Marketing Application for HEPLISAV™".